Clinical Trial Update: A Trial of SHR-1701 in Combination With Gemcitabine and Albumin Paclitaxel in Patients With Pancreatic Cancer [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating SHR-1701 in combination with gemcitabine and albumin-bound paclitaxel in pancreatic cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Drugs mentioned

• Gemcitabine (Gemcitabine)
• Nab-paclitaxel (paclitaxel protein-bound)
• SHR-1701

Snippet

Sponsor: Jiangsu HengRui Medicine Co., Ltd. | Conditions: Pancreatic Cancer | Phase 1, Phase 2 | Status: COMPLETED